Multiplex Assay Kit for Orosomucoid 2 (ORM2) ,etc. by FLIA (Flow Luminescence Immunoassay)

AGP-B; AGP2; Alpha-1-Acid Glycoprotein Type 2

(Note: Up to 8-plex in one testing reaction)

Specificity

This assay has high sensitivity and excellent specificity for detection of Orosomucoid 2 (ORM2) ,etc. by FLIA (Flow Luminescence Immunoassay).
No significant cross-reactivity or interference between Orosomucoid 2 (ORM2) ,etc. by FLIA (Flow Luminescence Immunoassay) and analogues was observed.

Recovery

Matrices listed below were spiked with certain level of recombinant Orosomucoid 2 (ORM2) ,etc. by FLIA (Flow Luminescence Immunoassay) and the recovery rates were calculated by comparing the measured value to the expected amount of Orosomucoid 2 (ORM2) ,etc. by FLIA (Flow Luminescence Immunoassay) in samples.

Matrix Recovery range (%) Average(%)
serum(n=5) 95-102 99
EDTA plasma(n=5) 97-105 101
heparin plasma(n=5) 81-98 95

Precision

Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Orosomucoid 2 (ORM2) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Orosomucoid 2 (ORM2) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%

Linearity

The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Orosomucoid 2 (ORM2) ,etc. by FLIA (Flow Luminescence Immunoassay) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample 1:2 1:4 1:8 1:16
serum(n=5) 79-89% 88-95% 99-105% 93-101%
EDTA plasma(n=5) 84-98% 96-103% 79-95% 81-101%
heparin plasma(n=5) 79-96% 94-105% 99-105% 90-101%

Stability

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Reagents and materials provided

Reagents Quantity Reagents Quantity
96-well plate 1 Plate sealer for 96 wells 4
Pre-Mixed Standard 2 Standard Diluent 1×20mL
Pre-Mixed Magnetic beads (22#:ORM2) 1 Analysis buffer 1×20mL
Pre-Mixed Detection Reagent A 1×120μL Assay Diluent A 1×12mL
Detection Reagent B (PE-SA) 1×120μL Assay Diluent B 1×12mL
Sheath Fluid 1×10mL Wash Buffer (30 × concentrate) 1×20mL
Instruction manual 1

Assay procedure summary

1. Preparation of standards, reagents and samples before the experiment;
2. Add 100μL standard or sample to each well,
    add 10μL magnetic beads, and incubate 90min at 37°C on shaker;
3. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60min at 37°C on shaker;
4. Wash plate on magnetic frame for three times;
5. Add 100μL prepared Detection Reagent B, and incubate 30 min at 37°C on shaker;
6. Wash plate on magnetic frame for three times;
7. Add 100μL sheath solution, swirl for 2 minutes, read on the machine.

GIVEAWAYS

INCREMENT SERVICES

Magazine Citations
Clin Exp Nephrol Differentially expressed urinary biomarkers in children with idiopathic nephrotic syndrome PubMed: 26351173
Free Patents online RHEUMATOID ARTHRITIS RELATED BIOMARKER 20170350884
Osteoarthritis and Cartilage Orosomucoid 2 serves for predicting but not for monitoring drug response in patients with knee osteoarthritis treated with chondroitin sulfate/glucosamine … 10.1016:j.joca.2018.02.412
Therapeutic Advances in Chronic Disease Predictive modeling of therapeutic response to chondroitin sulfate/glucosamine hydrochloride in knee osteoarthritis
Journal of Cosmetic Dermatology Evaluation of serum and urinary orsomucoid protein A in psoriatic patients and their relation to severity of disease 33905172
Catalog No. Related products for research use of Homo sapiens (Human) Organism species Applications (RESEARCH USE ONLY!)
RPB780Hu01 Recombinant Orosomucoid 2 (ORM2) Positive Control; Immunogen; SDS-PAGE; WB.
CPB780Hu21 OVA Conjugated Orosomucoid 2 (ORM2) Immunogen; SDS-PAGE; WB.
PAB780Hu01 Polyclonal Antibody to Orosomucoid 2 (ORM2) WB; IHC; ICC; IP.
LAB780Hu81 FITC-Linked Polyclonal Antibody to Orosomucoid 2 (ORM2) WB; IHC; ICC; IF.
LAB780Hu71 Biotin-Linked Polyclonal Antibody to Orosomucoid 2 (ORM2) WB; IHC; ICC.
MAB780Hu22 Monoclonal Antibody to Orosomucoid 2 (ORM2) WB; IHC
MAB780Hu21 Monoclonal Antibody to Orosomucoid 2 (ORM2) WB; IHC; ICC; IP.
SEB780Hu ELISA Kit for Orosomucoid 2 (ORM2) Enzyme-linked immunosorbent assay for Antigen Detection.
LMB780Hu Multiplex Assay Kit for Orosomucoid 2 (ORM2) ,etc. by FLIA (Flow Luminescence Immunoassay) FLIA Kit for Antigen Detection.